C2N Diagnostics Announces Successful Completion of Milestones Under $300,000 Alzheimer's Drug Discovery Foundation Award

Published: Nov 12, 2009

ST. LOUIS, MO – C2N Diagnostics reported today that it has successfully accomplished each of the milestones defined under its partnership with the Alzheimer’s Drug Discovery Foundation (ADDF) and ADDF’s affiliate, the Institute for the Study of Aging. Under the terms of the collaborative financing, ADDF awarded $300,000 to C2N for the purpose of readying the company to perform an industry-grade SILK-Aß™ assay.

Back to news